Effectiveness of low-dose atropine in pediatric myopia management: insights from NIO and H, Dhaka
DOI:
https://doi.org/10.18203/2349-3291.ijcp20251466Keywords:
Atropine, Axial length, Myopia, Refractive status, Visual acuityAbstract
Background: Myopia, the most common refractive error, is becoming a significant public health challenge due to its rising incidence and associated risks of vision impairment and ocular complications. Low-dose atropine (0.01%) is a promising intervention hypothesized to slow myopia progression by modulating retinal and scleral signaling and reducing axial elongation. Unlike higher concentrations, it has fewer side effects, making it suitable for long-term use in children.
Methods: This prospective comparative study was conducted at the National Institute of Ophthalmology and Hospital in Dhaka, Bangladesh, from June 2023 to July 2024. Fifty-six myopic children aged 6–14 years were divided into two equal groups: one received atropine 0.01% eye drops (Atropine group), while the other received no atropine (Control group). Refractive status (RS) and axial length (AL) were assessed over 12 months using SPSS 26 for data analysis.
Results: Forty-six participants (92 eyes) completed the study. Children aged 6–10 years in the atropine group showed significantly less myopia progression (-0.04±0.09 D vs. -0.38±0.23 D, p<0.0001) and axial length elongation (0.03±0.02 mm vs. 0.21±0.05 mm, p<0.0001). In the 11–14 years subgroup, axial length growth was significantly slower in the atropine group (0.04±0.05 mm vs. 0.20±0.05 mm, p<0.0001), though refractive error differences were not statistically significant. Temporary photophobia was reported in 4.5% of atropine users, with no other adverse effects.
Conclusions: Atropine 0.01% eye drops effectively slow the progression of myopia and axial length growth in children aged 6–14 years.
Metrics
References
Baird PN, Seang-Mei S, Carla L. Myopia (Primer). Disease Primers. 2020;6(1):1-23. DOI: https://doi.org/10.1038/s41572-020-00239-w
Li FF, Yam JC. Low-concentration atropine eye drops for myopia progression. The Asia-Pacific J Ophthalmol. 2019;8(5):360-5. DOI: https://doi.org/10.1097/APO.0000000000000256
Wong YL, Saw S. Epidemiology of Pathologic Myopia in Asia and Worldwide. Asia-Pacific journal of ophthalmol. 2016;5:394-402. DOI: https://doi.org/10.1097/APO.0000000000000234
Bourne RR, Dineen BP, Ali SM, Huq DM, Johnson GJ. Prevalence of refractive error in Bangladeshi adults: results of the National Blindness and Low Vision Survey of Bangladesh. Ophthalmol. 2004;111(6):1150-60.
Chia A, Chua WH, Cheung YB. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1% and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmol. 2012;119(2):347-54.
Clark TY, Clark R. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Therap. 2015;31(9):541-5.
Walline JJ, Lindsley KB, Vedula SS. Interventions to slow progression of myopia in children. Cochrane Database of Systematic Reviews. 2021;2:1-124.
Fang Y, Chou Y, Pu C. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye. 2013;27(3):418-24.
Moriche-Carretero M, Revilla-Amores R, Diaz-Valle D. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. J Francais d'Ophtalmologie. 2021;44(10):1499-504.
Sen S, Yadav H, Jain A. Effect of atropine 0.01% on progression of myopia. Indian Jo Ophthalmol. 2022;70(9):3373-6.
Bourne RR, Dineen BP, Ali SM, Huq DM, Johnson GJ. Prevalence of refractive error in Bangladeshi adults: results of the National Blindness and Low Vision Survey of Bangladesh. Ophthalmology. 2004 Jun 1;111(6):1150-60. DOI: https://doi.org/10.1016/j.ophtha.2003.09.046
Chia, A., Chua, W.-H., Cheung, Y.-B., Wong, W.L., Lingham, A., Fong, A. and Tan, D. 2012. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 119(2), pp.347-354. DOI: https://doi.org/10.1016/j.ophtha.2011.07.031
Clark, T.Y., Clark, R. 2015. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. Journal of ocular pharmacology and therapeutics. 31(9), pp.541-545. DOI: https://doi.org/10.1089/jop.2015.0043
Walline, J.J., Lindsley, K.B., Vedula, S.S., Cotter, S.A., Mutti, D.O., Ng, S.M. and Twelker, J.D.J.C.D.o.S.R. 2020. Interventions to slow progression of myopia in children. Cochrane Database of Systematic Reviews. pp. 1-124. DOI: https://doi.org/10.1002/14651858.CD004916.pub4
Fang, Y., Chou, Y., Pu, C., Lin, P., Liu, T., Huang, N. and Chou, P.J.E. 2013. Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study. Eye. 27(3), pp.418-424. DOI: https://doi.org/10.1038/eye.2012.279
Moriche-Carretero, M., Revilla-Amores, R., Diaz-Valle, D., Morales-Fernández, L. and Gomez-de-Liaño, R. 2021. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. Journal Francais d'Ophtalmologie. 44(10), pp.1499-1504. DOI: https://doi.org/10.1016/j.jfo.2021.07.005
Sen, S., Yadav, H., Jain, A., Verma, S. and Gupta, P. 2022. Effect of atropine 0.01% on progression of myopia. Indian Journal of Ophthalmology. 70(9), pp.3373-3376. DOI: https://doi.org/10.4103/ijo.IJO_256_22
Downloads
Published
How to Cite
Issue
Section
